September 2005 Archives
Viacell to Present at UBS Healthcare Conference
Cambridge, MA, September 21, 2005 ― ViaCell, Inc. (Nasdaq: VIAC) today announced that the company will present at the UBS Global Life Sciences Conference taking place September 26 - 29, 2005 at the Grand Hyatt New York in New York City.
Marc D. Beer, President and Chief Executive Officer, will present an overview of ViaCell’s business activities and product pipeline at 11:00 a.m. on Monday, September 26, 2005.
...Continue reading "Viacell to Present at UBS Healthcare Conference"
Posted on September 27, 2005 05:59 PM | Comments (0)
ThermoGenesis to Present at the UBS Global Life Science Conference
RANCHO CORDOVA, Calif., Sept. 22 - ThermoGenesis Corp. (Nasdaq: KOOL) announced today that Philip Coelho, Chairman and Chief Executive Officer, will participate in the UBS Global Life Science Conference on Wednesday, September 28, 2005 at 3:00 pm EDT.
Mr. Coelho will present an overview of the company's business activities and product pipeline. The UBS Conference will be held at the Grand Hyatt Hotel in New York, NY.
Continue reading "ThermoGenesis to Present at the UBS Global Life Science Conference"
Posted on September 27, 2005 05:46 PM | Comments (0)
Viacell Suspends Enrollment in CB001 Phase I Clinical Trial
Cambridge, MA, September 19, 2005 - ViaCell, Inc. (NASDAQ: VIAC) today announced that it has suspended enrollment in its Phase I clinical trial of CB001, an investigational cord blood stem cell product for hematopoietic stem cell transplantation being studied for the treatment of a variety of cancers.
Of the eight patients who have completed treatment in the study, two experienced Grade IV acute graft-versus-host-disease, or aGVHD, a known potential side effect in transplantation. Both patients have recovered from the aGVHD, however, under the study protocol, the occurrence of two cases calls for a suspension of enrollment in the trial.
...Continue reading "Viacell Suspends Enrollment in CB001 Phase I Clinical Trial"
Posted on September 27, 2005 05:37 PM | Comments (0)
CRYO-CELL Announces Strategic Alliances To Reach Consumer Markets
Company Signs Exclusive Agreements with Upromise(R) and Real Savvy Moms(TM)
OLDSMAR, Fla., Sept. 19 - CRYO-CELL International, Inc. (OTCBB: CCEL) announced today that it has signed a definitive agreement with Upromise, Inc. to continue the Company's participation in Upromise's industry-leading college savings service.
Under the terms of this exclusive agreement, CRYO-CELL will continue as the first, and only, cord blood stem cell preservation firm to team up with Upromise to help consumers save for college.
...Continue reading "CRYO-CELL Announces Strategic Alliances To Reach Consumer Markets"
Posted on September 27, 2005 05:32 PM | Comments (0)
Stem Cell Therapy International Corp. is Acquired by Altadyne
Stem Cell Therapy International Corp., (OTC: ATYD.PK), a company devoted to the sale and distribution of biological solutions containing stem cell products, today announced it has been acquired by Altadyne, Inc., a Nevada corporation.
Stem Cell Therapy International Corp. CEO and President Calvin Cao and Chief Financial Officer Daniel Sullivan have assumed the same titles in the newly merged company and both were appointed to its Board of Directors.
...Continue reading "Stem Cell Therapy International Corp. is Acquired by Altadyne"
Posted on September 23, 2005 12:23 PM | Comments (0)
MultiCell Technologies Appoints Anthony Altig to Board
Experienced Biotechnology Executive to Help Company Develop Therapeutic Platform
LINCOLN, RI – September 19, 2005 – Multicell Technologies, Inc. (OTCBB:MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery, announced today that it has appointed Anthony Altig to the Company's Board of Directors.
Mr. Altig has extensive experience in financial management, strategic planning and SEC reporting, as well as investor relations, budgeting, treasury, tax planning and risk management.
...Continue reading "MultiCell Technologies Appoints Anthony Altig to Board"
Posted on September 23, 2005 11:36 AM | Comments (0)
Healtheuniverse Announces New Chief Medical Officer and Co-Head of Regenerative Cell and Stem Cell Research
Dr. Slattery and Dr. Dev to Coalesce and Lead Accomplished Team of Researchers in Exploring the Full Ability of Non-Embryonic Stem Cells to Transform Medicine
COVINA, CA - 09/13/2005 - Healtheuniverse, Inc. (OTC: HLUN), a biotechnology development firm specializing in the development and commercialization of biopharmaceutical and biomedical products announced today the appointment of Kevin Slattery M.D. to the position of Chief Medical Officer and Co-Head of Regenerative Cell and Stem Cell Research.
He will assume a full suite of responsibilities working with Healtheuniverse CEO Vipul Dev - including stem cell research applications, patent application submission, approval, and development of proprietary biopharmaceutical and biomedical products.
...Posted on September 22, 2005 06:16 PM | Comments (0)
Geron Corporation Announces Exercise Of Over-Allotment Option
Menlo Park, CA – September 20, 2005 – Geron Corporation (Nasdaq: GERN) today announced that on Monday, September 19, 2005, the underwriters of its public offering of six million shares of common stock have exercised their over-allotment option in full to purchase 900,000 additional shares, resulting in an additional gross public offering price of $8.1 million.
The public offering and over-allotment exercise are expected to close on September 21, 2005.
...Continue reading "Geron Corporation Announces Exercise Of Over-Allotment Option"
Posted on September 22, 2005 06:08 PM | Comments (0)
MultiCell Technologies Awarded Pilot Grant for Study of Type 1 Diabetes Therapeutic
LINCOLN, R.I. – September 14, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and a supplier of immortalized non-tumorigenic human hepatocytes for drug discovery applications, announced today that it has been awarded a pilot grant for an a pilot study for type 1 diabetes using its proprietary Immunoglobulin Therapeutic.
Sponsored by the UCHSC-NIAID subcontract FY05-062.012 sponsor # U19 AI050864-04, the study will be conducted in collaboration with the Benaroya Research Institute at Virginia Mason University in Seattle, Washington.
...Posted on September 22, 2005 05:42 PM | Comments (0)
Progenitor Cell Therapy Inks Manufacturing Deal with Cellerant Therapeutics to Bring Stem Cell Treatment to Market
Progenitor Cell Therapy, LLC (PCT), a leading cell engineering and cell therapy services company, announced today that its cGMP facility in Mountain View, California will serve as the manufacturing site for Cellerant Therapeutics, Inc.’s (Cellerant) premier product.
Hackensack, NJ (PRWEB) September 13, 2005 - Progenitor Cell Therapy, LLC (PCT), a leading cell engineering and cell therapy services company, announced today that its cGMP facility in Mountain View, California will serve as the manufacturing site for Cellerant Therapeutics, Inc.’s (Cellerant) premier product.
...Posted on September 22, 2005 05:39 PM | Comments (0)
MultiCell Forms New Company to Develop Novel Therapies for Diabetes and Other Autoimmune Diseases
LINCOLN, R.I. – Sept. 7, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and a supplier of immortalized non-tumorigenic human hepatocytes for drug discovery applications, announced that it has formed a new company, MultiCell Immunotherapeutics, Inc. ("MCTI"). MCTI will be a majority-owned subsidiary of MCET that will develop new therapeutic products utilizing stem cells and other related technologies.
In connection with these efforts, MultiCell announced that MCTI has acquired certain intellectual property and certain other assets, including laboratory equipment and key employees, of Astral, Inc. ("Astral"), a San Diego biotechnology company developing novel therapies for the treatment of type 1 diabetes, multiple sclerosis, cancer and infectious disease.
...Posted on September 22, 2005 05:35 PM | Comments (0)
Geron Corporation Announces The Pricing Of Its Common Stock Offering
Menlo Park, CA – September 16, 2005 – Geron Corporation (Nasdaq: GERN) today reported that its previously announced underwritten public offering of six million shares of common stock was priced at $9.00 per share. The gross public offering price from this underwritten public offering, which is expected to close on September 21, 2005, will be $54.0 million.
Concurrent with the closing of the underwritten public offering, Merck & Co., Inc. (NYSE: MRK) will exercise a warrant to purchase shares of Geron common stock with a total exercise price of $18.0 million.
...Continue reading "Geron Corporation Announces The Pricing Of Its Common Stock Offering"
Posted on September 22, 2005 05:31 PM | Comments (0)
U.S. BioDefense Receives Positive Industry Response to Neural Stem Cell Technology at Inaugural Stem Cell Research Conference
CITY OF INDUSTRY, Calif. - Sept. 13, 2005 - U.S. BioDefense, Inc. (OTCBB:UBDE) announces successful sponsorship of the Cambridge Healthtech Institute's Inaugural "Stem Cell Research" conference recently hosted at the University Park Hotel at MIT in Cambridge, Mass., from August 29th thru August 31st, 2005.
Director of Research Dr. Cyndi Chen was in attendance to chair the session on Realizing Therapeutic Potential and to build awareness of the company and its Neural Crest Stem Cell commercialization strategy.
...Posted on September 22, 2005 05:23 PM | Comments (0)
Cord Blood America Secures $5 Million Financing Agreement
LOS ANGELES, Sept. 13, 2005 - Cord Blood America, Inc. (OTCBB:CBAI), an umbilical cord blood stem cell preservation company, is pleased to announce that it has closed a financing arrangement with Cornell Capital Partners, LP ("Cornell") providing the company an additional $5,000,000 in funding.
With this latest agreement, Cornell will purchase $5,000,000 in secured convertible debentures. The company received $3,500,000 on September 9, 2005. The remaining $1,500,000 will be provided upon filing of the registration statement.
...Continue reading "Cord Blood America Secures $5 Million Financing Agreement"
Posted on September 22, 2005 04:38 PM | Comments (0)
Markers Of Brain Cell Development May Help Success Of Stem Cell Transplants
Four sugar-coated faces made by stem cells as they differentiate into brain cells during development have been identified by scientists.
These unique expressions of sugar on the cell surface may one day enable stem cell therapy to repair brain injury or disease by helping stem cells navigate the relative "jungle" of the adult brain, says Dr. Robert K. Yu, director of the Institute of Neuroscience and the Institute for Molecular Medicine and Genetics at the Medical College of Georgia.
...Continue reading "Markers Of Brain Cell Development May Help Success Of Stem Cell Transplants"
Posted on September 22, 2005 04:33 PM | Comments (0)
Geron Corporation Announces Common Stock Offering
MENLO PARK, Calif.- Sept. 12, 2005 - Geron Corporation (Nasdaq:GERN) today announced its plans to offer six million shares of its common stock in an underwritten offering made from effective shelf registration statements. Concurrent with the underwritten offering, Merck & Co., Inc. (NYSE:MRK) will exercise its warrant to purchase $18 million of Geron common stock.
UBS Investment Bank is acting as the sole book running manager in this offering. SG Cowen & Co., LLC, Needham & Company LLC and Lazard Capital Markets LLC are acting as co-managers.
...Continue reading "Geron Corporation Announces Common Stock Offering"
Posted on September 22, 2005 04:25 PM | Comments (0)
Cytori Therapeutics Demonstrates Adipose-Derived Adult Stem and Regenerative Cells Enhance Cardiac Function in Preclinical Study
Data Featured in One of Four Cytori Presentations at Annual Adipose Biology Meeting
San Diego, CA, September 12, 2005 - Cytori Therapeutics, Inc. (Frankfurt: XMP), today announced preclinical results that support therapeutic opportunities for adult stem and regenerative cells derived from adipose, also known as fat tissue, in the treatment of cardiac injury following acute myocardial infarction (heart attack).
These data, along with three other Cytori presentations, are being featured at the third annual International Fat Applied Technology Society conference September 10-13, 2005 in Charlottesville, Virginia.
...Posted on September 22, 2005 04:19 PM | Comments (0)
Key To Stem Cell Transplant Success Is Tricking Immune System
According to Professor Maggie Dallman, Imperial College London, tricking the bodys immune system into ignoring stem cells will be the key to successful stem cell transplants.
Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture.
...Continue reading "Key To Stem Cell Transplant Success Is Tricking Immune System"
Posted on September 22, 2005 04:13 PM | Comments (0)
Advanced Cell Technology Raises $17.75 Million through Private Placement of Convertible Notes and Warrants
Worcester, MA – Advanced Cell Technology, Inc. (OTCBB: ACTC.OB) announced today that it has closed a private placement of convertible notes and warrants to raise proceeds of $17.75 million dollars.
The convertible notes are convertible into 9,672,925 million shares of common stock at a price of $2.30 per share.
...Posted on September 22, 2005 04:02 PM | Comments (0)
Californian Heart Disease Patient Shows Improvement After Stem Cell Therapy
Improvement of California woman stuns her cardiologist one month after receiving stem cell treatment in Bangkok, Thailand.
Palo Verde, CA (PRWEB) September 9, 2005 - Dee Coats, the first Californian to receive VesCell™ stem cell therapy for heart disease is featured in the September 1st issue of the Palo Verde Valley Times.
The story, "Blythe woman’s trip to Bangkok repairs damaged heart" authored by Marty Bachman can be found on the Palo Verde Valley Times home page.
...Continue reading "Californian Heart Disease Patient Shows Improvement After Stem Cell Therapy"
Posted on September 22, 2005 03:55 PM | Comments (0)
Published Study Shows First Direct Link Between Human Neural Stem Cells and Restored Motor Function in Spinal Cord Injured Mice
StemCells Inc.’s Adult Human Neural Stem Cells Regenerate Protective Layer Around Nerves Following Spinal Cord Injury
PALO ALTO, Calif., (September 19, 2005) – StemCells, Inc. (Nasdaq: STEM) today announced results of a published study that demonstrates that the Company’s proprietary human neural stem cells restore the lost motor function of mice with spinal cord injuries.
This study is also the first to show the causal relationship between transplanted human neural stem cells and long-term recovery of motor function: The human neural cells were subsequently ablated in some of the mice, and their improved motor function was lost.
...Posted on September 21, 2005 09:53 AM | Comments (0)
StemCells, Inc. Announces Filing of IND Amendment for Human Neural Stem Cell Transplant Treatment for Batten Disease
PALO ALTO, Calif., (September 19, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced the filing with the U.S. Food and Drug Administration (FDA) of an amendment to its initial IND (Investigational New Drug) application to begin a clinical trial of its human neural stem cells (HuCNS-SC) as a treatment for Batten disease.
Batten disease is a rare and fatal neurodegenerative genetic condition affecting infants and children. The proposed Phase I trial has been on hold since February 2005, pending a complete response to questions and concerns presented to the Company by the FDA.
...Posted on September 20, 2005 04:43 PM | Comments (0)
National Sickle Cell Awareness Month
New York Blood Center, Kings County HospitalCenter, Civic Leaders Call on Brooklyn Community to Donate Blood
In recognition of National Sickle Cell Awareness Month (September), Kathleen Grima, MD, Acting Chief Medical Officer, New York Blood Center (NYBC) and Jean G. Leon, RN, MPA, Senior Vice President, Central Brooklyn Family Health Network and Executive Director, Kings County Hospital Center will be joined by healthcare leaders, patients and their families to raise awareness of the disease and the need for blood donors in the Brooklyn community today (Sept. 19) 10:30AM, at Kings County Hospital Center, 471 Clarkson Avenue, Brooklyn.
...Continue reading "National Sickle Cell Awareness Month"
Posted on September 19, 2005 05:41 PM | Comments (0)
Multicell Held Grand Opening At Rhode Island Facilities; Governor Carcieri Was Featured Speaker
LINCOLN, RI September 16, 2005 – Multicell Technologies, (NASDAQ:MCET.OB), whose scientists are known for two key discoveries heretofore not accomplished by other scientists: two patents on ADULT human liver stem cells and functional immortalized non-tumorigenic liver cells, held a grand opening ceremony Thursday, September 15.
Since settling into its new laboratory facilities and offices at 701 George Washington Highway in Lincoln, MultiCell has added additional equipment and technical and administrative staff.
Posted on September 14, 2005 06:12 PM | Comments (0)
Isolation of Adult Muscle Stem Cells for Skeletal Muscle Repair
EuroStemCell researchers from the Institut Pasteur have isolated muscle stem cells displaying a high potential for muscle repair. These stem cells are much more effective in promoting muscle repair than the cultured cells previously used. This work, published on September 1st in Science, tells us more about adult muscle stem cells and sheds new light on the potential of these cells in the treatment of muscular defects.
Following the successful use of blood stem cells to reconstitute cells damaged in diseases like leukaemia, researchers have been interested in the use of other types of stem cells to repair adult tissue damaged through injury or degenerative disease. However, it has until now been difficult to isolate pure populations of adult stem cells in large numbers.
...Continue reading "Isolation of Adult Muscle Stem Cells for Skeletal Muscle Repair"
Posted on September 13, 2005 06:10 PM | Comments (0)
PharmaFrontiers to Present at ValueRich Small Cap Financial Exposition
PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, will make a presentation at the ValueRich Small-Cap Financial Expo 2005 which will be held at the Jacob K. Javits Convention Center on September 14 and 15 in New York City.
PharmaFrontiers' Chief Financial Officer, William Rouse, will deliver the presentation on Thursday, September 15 at 11:00 a.m. Eastern Time in which he will discuss the Company's clinical program to develop and commercialize cell therapies to treat several major disease areas including Multiple Sclerosis and cardiac and pancreatic conditions.
...Continue reading "PharmaFrontiers to Present at ValueRich Small Cap Financial Exposition"
Posted on September 13, 2005 05:27 PM | Comments (0)
StemCells Appoints Rodney K.B. Young CFO and VP, Finance
PALO ALTO, Calif., (September 7, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced the appointment of Rodney K.B. Young as Chief Financial Officer and Vice President, Finance, effective September 6, 2005.
Young brings financial and administrative experience in the healthcare field to the Company, including extensive international experience in healthcare investment banking.
...Continue reading "StemCells Appoints Rodney K.B. Young CFO and VP, Finance"
Posted on September 9, 2005 07:02 PM | Comments (0)
Geron Announces Publications Demonstrating Efficacy Of GRN163l
Menlo Park, CA – Sept 6, 2005 – Geron Corporation (Nasdaq: GERN) announced today publications demonstrating efficacy of GRN163L, its pan-cancer telomerase inhibitor drug, in mouse models of human hepatocellular carcinoma and human metastatic lung cancer. The studies confirm and extend the broad potential of GRN163L for the treatment of cancer, and provide insights into how GRN163L works in inhibiting tumor growth and tumor metastases. GRN163L is currently in clinical testing in a Phase I/II trial in patients with chronic lymphocytic leukemia (CLL). Additional trials are being planned.
...Continue reading "Geron Announces Publications Demonstrating Efficacy Of GRN163l"
Posted on September 9, 2005 06:50 PM | Comments (0)
ThermoGenesis Corp. Announces Fourth Quarter and Year End Results
Three (3) Essential Milestones Completed for the Company: AXP Development, Completion of CryoSeal US Pivotal Trial Enrollment and TPD European Launch
RANCHO CORDOVA, Calif., Sept. 9, 2005 - ThermoGenesis Corp. (NASDAQ-SCM: KOOL) today announced results for its fourth quarter and year ended June 30, 2005. Net revenues for the quarter ended June 30, 2005 were $3,099,000, a reduction of 15% compared to $3,636,000 for the fourth quarter of fiscal 2004. For the year ended June 30, 2005, the Company's net revenues were $10,177,000, a reduction of 13% compared to $11,646,000 for the prior year.
...Continue reading "ThermoGenesis Corp. Announces Fourth Quarter and Year End Results"
Posted on September 9, 2005 04:07 PM | Comments (0)
A New Link Between Stem Cells and Tumors
Scientists at the European Molecular Biology Laboratory [EMBL] in Heidelberg and the Institute of Biomedical Research of the Parc Científic de Bar de Barcelona [IRB-PCB] in Spain have now added key evidence to claims that some types of cancer originate with defects in stem cells. The study, reported this week in the on-line edition of Nature Genetics [September 4] shows that if key molecules aren't placed in the right locations within stem cells before they divide, the result can be deadly tumors.
Cells in the very early embryo are interchangeable and undergo rapid division. Soon, however, they begin differentiating into more specific types, finally becoming specialized cells like neurons, blood, or muscle. As they differentiate, they should stop dividing and usually become embedded in particular tissues. Some tumor cells are more like stem cells because they are identical, they divide quickly, and in the worst case metastasize they wander through the body and implant themselves in new tissues.
...Continue reading "A New Link Between Stem Cells and Tumors"
Posted on September 9, 2005 03:27 PM | Comments (0)
Stem Cell Media Advisory: Leaders in Adult Stem Cells Derived from Fat to Hold News Conference
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Sep 8, 2005 - The growing therapeutic role of adult stem cells derived from adipose, also known as fat tissue, will be highlighted at a news conference to be held Monday, September 12, 2005, 12:30-1:45 pm Eastern at the 2005 International Fat Applied Technology Society (IFATS) scientific meeting in Charlottesville, VA.
The third annual IFATS conference will host 47 abstract presentations from around the world. These abstracts will demonstrate the ability of adipose adult stem cells to repair or regenerate new blood vessels, cardiac muscle, nerves, bones and other tissues potentially helping patients dealing with heart attack, brain and spinal cord injuries, and osteoporosis.
...Posted on September 9, 2005 03:24 PM | Comments (0)
Stem Cells Found in Heart Tissue
With all the news as of late with Katrina and the like .. we have been hard pressed to keep on top of other developments.
However, as we pray for the survivors and hope the best for all those affected, we thought it was time for us to get started back some before we have a last vacation (yes .. Labor Day we had to miss).
Anyway .. the latest news comes from stem cell researchers in Japan who have discovered stem cells in human heart tissue. The hope of this latest finding is that it could possibly lead to improved heart disease treatments and further reducing the need for heart transplants.
...Continue reading "Stem Cells Found in Heart Tissue"
Posted on September 9, 2005 03:03 PM | Comments (0)
ChemokineTherapeutics Publishes First Demonstration of Enhanced Survival, Expansion, and Engraftment of Human Cord Blood Stem Cells using Synthetic SDF-1 Analog
Vancouver, BC (September 6, 2005) – Chemokine Therapeutics Corp. (OTCBB: CHKT; TSX: CTI), a biotechnology company developing peptide-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that it has discovered yet another therapeutic application for its chemokine analog, CTCE-0214.
The discovery, which is published in the Journal Stem Cells, demonstrated that the Company’s second lead product CTCE-0214 significantly multiplied the number of stem cells and related progenitor cell subsets from human cord blood through a process called ex-vivo expansion.
...Posted on September 8, 2005 01:37 PM | Comments (0)
New Stem Cell Mobilizer Improves Cancer Patient Chances For Stem Cell Transplantation
Vancouver, BC, September 6, 2005 - A study published in the current issue of the peer-reviewed journal, Blood, demonstrates that cancer patients who received AMD3100 (MOZOBIl) plus granulocyte-colony stimulating factor (G-CSF) were able to collect more stem cells in less time compared to the standard mobilization regimen, G-CSF alone.
"Cancer patients need better stem cell mobilization, as the strongest predictor of success in transplant is the number of cells available for transplantation", said study lead investigator Dr. Neal Flomenberg, Chief, Division of Medical Oncology, Thomas Jefferson University, Philadelphia, PA.
...Posted on September 8, 2005 01:28 PM | Comments (0)
Affymetrix Microarrays Uncover Genetic Mutations in Embryonic Stem Cells Approved for Federally-Funded Research
Scientists Report That Majority of Cells Develop Mutations Over Time
SANTA CLARA, Calif., Sep 04, 2005 - Affymetrix Inc. (Nasdaq:AFFX) announced today that a research group led by scientists at Johns Hopkins School of Medicine and the NIH used Affymetrix GeneChip(R) microarrays to discover that eight of the stem cell lines approved for federally-funded research have mutated, raising concern about the use of the remaining 14 approved cell lines in future research or therapeutic applications.
...Posted on September 8, 2005 01:18 PM | Comments (0)
UCSF Team Advances Probe Of Neural Stem Cell-Brain Tumor Link
Scientists are studying the earliest stages of embryonic and adult stem cell growth in the culture dish and in animal models with the ultimate goal of identifying the genetic missteps that cause such diseases as amyotrophic lateral sclerosis (ALS), and that account for some cases of birth defects and infertility. Scientists also are conducting studies on adult stem cells to determine whether disregulated stem cells cause some cancers.
...Continue reading "UCSF Team Advances Probe Of Neural Stem Cell-Brain Tumor Link"
Posted on September 8, 2005 01:06 PM | Comments (0)
K-State Establishes New Institute To Study Stem Cells
MANHATTAN, Kan., Sept. 2 /U.S. Newswire/ -- Scientists at Kansas State University have established the Midwest Institute for Comparative Stem Cell Biology to expand research around stem cells derived from the umbilical cord matrix after birth.
"This new institute is in a strategic position nationally to form collaborative relationships with other institutions," said K-State Provost M. Duane Nellis. "It will facilitate the type and amounts of comparative stem cell research that can be undertaken."
...Continue reading "K-State Establishes New Institute To Study Stem Cells"
Posted on September 6, 2005 05:39 PM | Comments (0)
Cord Blood America Launches Revolutionary Pricing Plan to Provide Affordable Umbilical Cord Blood Stem Cell Preservation
LOS ANGELES, Sept. 6, 2005 - Cord Blood America, Inc. (OTCBB:CBAI), an umbilical cord blood stem cell preservation company, is pleased to announce that Cord Partners, a Cord Blood America, Inc. company, has launched a revolutionary pricing plan that will make cord blood preservation affordable for nearly any family. Cord Partners is the first to market with this pricing plan in the stem cell storage industry.
No competitor's current payment plans can rival this model. The removal of significant financial barriers is expected to dramatically increase the percentage of parents who decide to store their newborn's umbilical cord blood stem cells, leading to industry growth and greater shareholder value for Cord Blood America.
...Posted on September 6, 2005 05:16 PM | Comments (0)
Debate On Storage And Usage Of Cord Blood
As we well know, umbilical cord blood has shown to provide benefits now, contrary to what has been considered for such a long time .. medical waste. The issue these days is that there is not enough information out there and most women (mothers) don't know about the benefits of its preservation or don't know where to donate.
The families that want to save the umbilical cord blood have two options: pay companies to store the stem cells for possible use in the future or give them to public banks, where they can be used now by people in need of stem cell transplants. Many these days usually go with the first option though.
...Continue reading "Debate On Storage And Usage Of Cord Blood"
Posted on September 2, 2005 08:04 PM | Comments (0)
International Stem Cell Meeting in Kobe, Japan
Asian, European and American scientists participate in high-level workshop on "Stem Cells in Reproduction and in the Brain"
A critical mass of leading experts will meet from 1st to 3rd September in Kobe, Japan, to discuss and summarize the current status in the highly contentious field of stem cell research and regenerative medicine. It is expected that the meeting will help to clarify the potential and remaining challenges of this promising research area. The workshop is jointly organized by the Ernst Schering Research Foundation (Germany), the Max Planck Society (Germany) and the Riken Center for Developmental Biology (Japan) as part of the "Germany in Japan year".
...Continue reading "International Stem Cell Meeting in Kobe, Japan"
Posted on September 2, 2005 05:37 PM | Comments (0)
Geron Announces Publication of Studies Demonstrating Engraftment of Human Embryonic Stem Cell-Derived Cardiomyocytes in the Rodent Heart
Menlo Park, CA – September 1, 2005 – Geron Corporation (Nasdaq: GERN) announced today the publication of studies showing that cardiomyocytes differentiated from human embryonic stem cells (hESCs) engraft when transplanted into the rat heart.
The results provide proof of concept that transplanted hESC-derived cardiomyocytes survive and retain properties of cardiomyocytes, important for their use in the treatment of heart failure and myocardial infarction.
...Posted on September 2, 2005 05:23 PM | Comments (0)
New Life Scientific, Inc. to Present at the ValueRich Small Cap Financial Exposition -- September 15, 2005
FREEHOLD, N.J., Sept. 1, 2005 - New Life Scientific, Inc. ("New Life") (OTCBB:NWLF), an emerging bio-tech company, today announced that it will be a presenting company at the 2005 ValueRich Small Cap Financial Exposition - being held at the Jacob K. Javits Convention Center on September 14 and 15.
...Posted on September 2, 2005 05:19 PM | Comments (0)
Invitrogen Promotes David Onions, Ph.D. to Chief Medical Officer
Scientific Leader to Help Company Transition toward Patient-Centric Support Technologies
CARLSBAD, Calif., Aug. 31, 2005 - Invitrogen Corporation (Nasdaq:IVGN) today promoted David Onions, Ph.D. to the newly created position of Chief Medical Officer.
In this new role, Dr. Onions will be responsible for guiding the company's scientific efforts as it moves into areas more closely associated with medical research and closer to patients, such as stem cell technologies, diagnostics support and other clinical studies.
...Continue reading "Invitrogen Promotes David Onions, Ph.D. to Chief Medical Officer"
Posted on September 2, 2005 05:15 PM | Comments (0)
Mesoblast Commences Bone Regeneration Trials At Colorado State University
Melbourne, Australia; 29 August 2005: Australian adult stem cell company, Mesoblast Limited (ASX:MSB), today announced it had commenced pre-clinical trials at Colorado State University in support of its Investigational New Drug (IND) submissions to the United States Food & Drug Administration (FDA).
Mesoblast is trialing its proprietary universal adult stem cells for treatment of long bone fractures and for spinal fusion.
...Continue reading "Mesoblast Commences Bone Regeneration Trials At Colorado State University"
Posted on September 2, 2005 05:06 PM | Comments (0)
Serologicals Corporation To Present At Thomas Weisel Partners Healthcare Conference 2005
ATLANTA, GA – August 31, 2005 – Serologicals Corporation (Nasdaq/NM: SERO) today announced that it is scheduled to give an investor presentation at the Thomas Weisel Partners Healthcare Conference on September 7, 2005.
Bud Ingalls, Vice President, Finance and Chief Financial Officer for Serologicals Corporation, will be making the presentation, scheduled for 9:45 a.m. (ET) at The Four Seasons Hotel in Boston, MA.
...Posted on September 2, 2005 04:19 PM | Comments (0)
StemCells, Inc. Receives Manufacturing License for Cell Processing Facility in California
PALO ALTO, Calif., (August 31, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced that it has received a manufacturing license for its cell processing facility from the State of California Department of Health Services, Food and Drug Branch.
This enables the Company to use its proprietary neural cell therapy product, HuCNS-SC, which is made at its licensed facility, in clinical trials.
...Posted on September 2, 2005 04:00 PM | Comments (0)
ViaCell Announces Publication of Preclinical Study Demonstrating That Umbilical Cord Stem Cells Improve Heart Function
CAMBRIDGE, Mass., Aug. 31 - ViaCell, Inc. (Nasdaq: VIAC) announced today the publication of results of a preclinical study demonstrating that administration of stem cells sourced from umbilical cord blood and using ViaCell's proprietary process significantly improved heart function in an in vivo model of myocardial infarction (heart attack).
The results of the preclinical study, sponsored by ViaCell and conducted in association with the Toronto General Research Institute at Toronto General Hospital under the supervision of Dr. Ren Ke-Li, have been published in the August 30,2005 Cardiovascular Surgery Supplement of Circulation: Journal of the American Heart Association.
...Posted on September 2, 2005 03:48 PM | Comments (0)
Family Cord Blood Services Assumes Leadership Role amongst Private Cord Blood Banks by Creating Choice for Clients to Make Cord Blood Stem Cells Available to the Public
Pioneer in Private Family Cord Blood Banking Leads Way to Help Grow Access to a Greater Public Pool of Cord Blood Stem Cells via "Public Donation" Option
Family Cord Blood Services, a leading umbilical cord blood bank and subsidiary of the California Cryobank, Inc., announced today a ground-breaking option that addresses the needs of both the general public and its private clients.
For the first time in the industry and in response to the increasing need for publicly donated cord blood, Family Cord Blood Services is offering a new and unique choice for families who want to privately bank cord blood.
...Posted on September 2, 2005 03:43 PM | Comments (0)
Umbilical Cord Blood Bank Pledges Donation to Alex's Lemonade Stand
Labor on Labor Day Funds Pediatric Cancer Research
PHILADELPHIA, Sept. 1 - CorCell, Inc., a national, private umbilical cord blood bank, announced today the promise of a monetary donation to Alex's Lemonade Stand, a foundation dedicated to funding pediatric cancer research. CorCell's donation will commemorate every baby delivered this Labor Day at partner hospitals in major cities across the United States.
CorCell's Labor Day initiative promises a significant donation to the non-profit organization founded by Alexandra "Alex" Scott, the young girl who established the research-minded charity while battling neuroblastoma, a childhood cancer currently being treated with stem cells found in umbilical cord blood.
...Continue reading "Umbilical Cord Blood Bank Pledges Donation to Alex's Lemonade Stand"
Posted on September 2, 2005 03:13 PM | Comments (0)
MultiCell Receives SBIR Grant for Protein Development for Critically Needed Sepsis Treatment
LINCOLN, R.I., Aug. 30, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading supplier of immortalized non-tumorigenic human hepatocytes, announces the receipt of a new Small Business Innovation Research (SBIR) award to create proprietary BioFactories that express a serine protease inhibitor recently implicated as a novel treatment for sepsis.
Sepsis is the leading cause of death in the non-cardiac intensive care unit and the tenth leading cause of death overall in the United States.
...Posted on September 1, 2005 08:23 PM | Comments (0)
U.S. BioDefense Stem Cell Initiative Positively Featured in California Newspaper
CITY OF INDUSTRY, Calif., Aug. 30, 2005 - U.S. BioDefense, Inc. (OTCBB:UBDE) was recently featured in the Wednesday, August 24, 2005 edition of the San Gabriel Valley Tribune, a leading Southern California Daily Newspaper (visit sgvtribune.com).
The article recognized the company's progress in the industry and its sponsorship of the Cambridge Healthtech Institute's Inaugural Stem Cell Research Conference. The Conference is being hosted at the University Park Hotel at MIT in Cambridge, Mass., and will run from August 29th, 2005 thru August 31st, 2005.
...Continue reading "U.S. BioDefense Stem Cell Initiative Positively Featured in California Newspaper"
Posted on September 1, 2005 07:56 PM | Comments (0)
ViaCell Announces Expansion of Amgen Collaboration and License Agreement and New Technology License from Johns Hopkins
BOSTON, Aug. 30 - ViaCell, Inc. (Nasdaq: VIAC) today announced that the Company has licensed from Amgen rights related to the use of recombinant human Granulocyte Colony Stimulating Factor (r-metHuG-CSF) for the development of a cellular therapy product to treat hematological malignancies and genetic diseases.
This license represents an expansion of ViaCell's collaboration and license agreement with Amgen, where ViaCell was previously provided a non-exclusive license to certain other Amgen growth factors for use in developing and manufacturing cell therapy products.
...Posted on September 1, 2005 07:36 PM | Comments (0)
Cytori Therapeutics Announces Fall Medical Conference Presentation Schedule
Results from Adipose Stem Cell Preclinical Studies to be Reported
San Diego, CA, August 30, 2005 - Cytori Therapeutics, Inc. (Frankfurt: XMP), announced today its Fall medical conference presentation schedule.
The Company will present preclinical results on the use of adult adipose stem and regenerative cells at the following meetings:
...Continue reading "Cytori Therapeutics Announces Fall Medical Conference Presentation Schedule"
Posted on September 1, 2005 07:23 PM | Comments (0)
XYTOS Announces Public Listing, Trading Sector, and Future of Company
INDIANAPOLIS, Aug. 29, 2005 - XYTOS, Inc. (the "Company") (Nasdaq:XYTS) is pleased to announce their public listing under the trading symbol of XYTS.
XYTOS will trade in the Bio-Medical Sector, with the goal to accelerate the future of the "Science of Medicine" by introducing next generation Bio-Medical Technologies in the areas of Stem Cell Therapies, Cellular Medicine And Tissue Engineering.
XYTOS will be announcing their Bio-Medical Technologies in the near future as well as a number of strategic relationships worldwide.
...Continue reading "XYTOS Announces Public Listing, Trading Sector, and Future of Company"
Posted on September 1, 2005 07:09 PM | Comments (0)
U.S. BioDefense Provides Updated Information About the Stem Cell Industry Council
CITY OF INDUSTRY, Calif., Aug. 26, 2005 (PRIMEZONE) - U.S. BioDefense, Inc. (OTCBB:UBDE), on July 28th, announced that it sponsored the successful launch of 1-800-STEM-CELLS.COM, a major success for the Stem Cell Industry Council, a newly formed IRS approved 501(C) (3) Nonprofit Organization "Advocating Stem Cell Education, Research, and Fundraising".
Today it would like to clarify that the Stem Cell Industry Council, Inc. is a Domestic Nonprofit Corporation in the process of registering as a foreign entity in California consisting of a consortium of industry members for advancing the Stem Cell Industry.
...Continue reading "U.S. BioDefense Provides Updated Information About the Stem Cell Industry Council"
Posted on September 1, 2005 06:58 PM | Comments (0)
South Africa - Study Shows Use of Stem Cells to Repair Damaged Heart Muscle
University of Cape Town and Stellenbosch University conducted a study on the use of stem cells repairing damaged heart muscle. Four male patients,aged 52, 65, 72 and 77, with end-stage heart failure took part in the study during 2004 and early 2005. All of them were unsuitable candidates for heart transplants. The surgery proved to be successful.
Johan Brink, professor of cardiothoracic surgery at the University of Cape Town medical faculty, will present the results of the procedure at the SA Transplant Congress in Malelane from Sunday to Friday this week, where it will for the first time be open to peer review.
...Continue reading "South Africa - Study Shows Use of Stem Cells to Repair Damaged Heart Muscle"
Posted on September 1, 2005 02:48 PM | Comments (0)